MYDA Advisors LLC Takes Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

MYDA Advisors LLC purchased a new position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 63,970 shares of the company’s stock, valued at approximately $301,000. MYDA Advisors LLC owned approximately 0.12% of Fulcrum Therapeutics at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. State Street Corp increased its position in shares of Fulcrum Therapeutics by 61.4% during the third quarter. State Street Corp now owns 1,680,229 shares of the company’s stock valued at $5,998,000 after acquiring an additional 638,955 shares in the last quarter. Barclays PLC raised its stake in shares of Fulcrum Therapeutics by 367.1% in the third quarter. Barclays PLC now owns 124,141 shares of the company’s stock worth $443,000 after purchasing an additional 97,565 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Fulcrum Therapeutics by 1.0% during the third quarter. Geode Capital Management LLC now owns 1,320,862 shares of the company’s stock valued at $4,716,000 after purchasing an additional 13,485 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Fulcrum Therapeutics by 5.9% during the fourth quarter. American Century Companies Inc. now owns 120,611 shares of the company’s stock valued at $567,000 after buying an additional 6,770 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in Fulcrum Therapeutics by 176.8% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 367,594 shares of the company’s stock worth $1,728,000 after buying an additional 234,810 shares during the last quarter. 89.83% of the stock is currently owned by institutional investors.

Fulcrum Therapeutics Price Performance

Shares of FULC stock opened at $3.29 on Friday. Fulcrum Therapeutics, Inc. has a 1 year low of $2.32 and a 1 year high of $10.13. The firm has a fifty day moving average price of $3.15 and a 200-day moving average price of $3.61. The company has a market cap of $177.59 million, a price-to-earnings ratio of -10.61 and a beta of 2.13.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03). Equities research analysts expect that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $8.63.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.